Last mentioned: Mar 20, 2026
Public Criticism
Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem.
Refusal to File
Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns.
Application Refusal
FDA senior regulator Vinay Prasad issues a formal refusal to review the flu vaccine application.
Grants Rescinded
The administration pulls back hundreds of millions in funding for mRNA-based research projects.
Grants Rescinded
White House rescinds hundreds of millions in mRNA research grants by year-end.
Workaround Supported
Regulators appear to support Moderna's plan to use data from a smaller trial to address dosage concerns.
Trial Design Support
FDA officials reportedly signal support for Moderna's flu vaccine trial workaround and data submission plan.
Collaboration Begins
FDA begins working closely with Moderna on its flu vaccine trial design.
Peak Valuation
Moderna reaches a market capitalization of $200 billion during the height of pandemic vaccine distribution.
House Republicans have introduced the Clean Water For All Life Act, a novel regulatory attempt to classify abortion pill remains as environmental pollutants. The bill seeks to mandate 'catch kits' for patients, ban mail-order medication, and impose severe criminal penalties on providers and users.
Moderna faces a significant regulatory setback as the FDA refuses to review its new flu vaccine, citing trial design flaws despite previous guidance. This shift reflects a broader, politically charged environment that threatens to destabilize the venture-backed biotech ecosystem.
The FDA's recent refusal to review Moderna's flu vaccine application marks a significant pivot in the regulatory environment for mRNA technology. This shift, characterized by increasing political pressure and unpredictable oversight, threatens to stifle the very innovation that defined the pandemic response.